When should a patient with statin‑induced myopathy start evolocumab (Repatha)?

When to Start Repatha in Statin-Induced Myopathy

Start Repatha immediately after confirming statin intolerance through a structured rechallenge protocol, without requiring a trial of ezetimibe first, particularly in patients with established cardiovascular disease or very high cardiovascular risk.

Clinical Approach

Step 1: Confirm True Statin Intolerance

Before initiating Repatha, verify that muscle symptoms are genuinely statin-related rather than coincidental. The GAUSS-3 trial 1 demonstrated that only 42.6% of patients reporting statin intolerance actually had symptoms confirmed by rechallenge—meaning over half had symptoms unrelated to statins.

Rechallenge protocol:

• Use atorvastatin 20 mg vs placebo in crossover fashion
• Document symptoms occurring with statin but not placebo
• This confirmation step prevents unnecessary use of expensive PCSK9 inhibitors in patients who could tolerate statins

Step 2: Initiate Repatha Without Delay in High-Risk Patients

For patients with established ASCVD (prior MI, stroke, or peripheral arterial disease):

• Start Repatha 140 mg subcutaneously every 2 weeks OR 420 mg monthly 22
• Do NOT require ezetimibe trial first
• The 2022 ACC guidelines 3 support PCSK9 inhibitors as adjunct therapy in ASCVD patients on maximally tolerated statin therapy (which may be zero dose in true intolerance)

For patients with very high cardiovascular risk (primary prevention):

• The 2022 BMJ guidelines 4 recommend adding PCSK9 inhibitors when LDL-C remains ≥100 mg/dL (2.6 mmol/L) despite maximally tolerated statin and ezetimibe
• However, in statin-intolerant patients, you can proceed directly to Repatha if LDL-C targets aren't met with ezetimibe alone

Step 3: Dosing Strategy

Standard dosing 2:

• 140 mg every 2 weeks (preferred in FOURIER trial—86% used this regimen)
• Alternative: 420 mg monthly (requires three 140-mg injections consecutively)

Expected outcomes:

• LDL-C reduction of 52.8-54.5% at 24 weeks 1
• Absolute LDL-C reduction of approximately 103-107 mg/dL
• Significantly superior to ezetimibe (which achieves only 16.7% reduction) 1

Key Evidence Supporting Immediate Use

The GAUSS-3 trial 1 specifically studied statin-intolerant patients and found:

• Evolocumab reduced LDL-C by 54.5% vs 16.7% with ezetimibe (p<0.001)
• Muscle symptoms occurred in only 20.7% on evolocumab vs 28.8% on ezetimibe
• Only 0.7% discontinued evolocumab for muscle symptoms vs 6.8% on ezetimibe

The FOURIER trial 22 demonstrated cardiovascular benefit:

• 15% relative risk reduction in primary composite endpoint (HR 0.85,95% CI 0.79-0.92)
• 20% relative risk reduction in CV death/MI/stroke (HR 0.80,95% CI 0.73-0.88)
• Median follow-up 26 months showed sustained benefit

Common Pitfalls to Avoid

Don't delay for ezetimibe trial in ASCVD patients: While guidelines mention sequential therapy, statin-intolerant patients with established cardiovascular disease need aggressive LDL-lowering immediately. Ezetimibe's modest 16.7% reduction 1 is insufficient for secondary prevention.

Don't assume all muscle symptoms are statin-related: The rechallenge protocol is critical—over half of reported symptoms are nocebo effects or unrelated conditions 1.

Don't worry about severe myopathy with Repatha: The GAUSS-3 trial 1 showed excellent muscle safety profile, with lower symptom rates than ezetimibe. This makes biological sense as PCSK9 inhibitors don't affect muscle metabolism like statins.

Monitor for rare immune-mediated necrotizing myopathy (IMNM): While this narrative focuses on typical statin myopathy, be aware that anti-HMG-CoA reductase antibody-positive IMNM 5 requires different management (immunosuppression) and can persist after statin discontinuation.

Practical Implementation

Baseline requirements before starting:

• Confirm LDL-C elevation (typically >70 mg/dL in ASCVD patients) 2
• Document statin intolerance with specific symptoms and CK levels if elevated
• Ensure patient is on maximally tolerated background therapy (even if zero statin)

Patient counseling:

• Subcutaneous injection technique (thigh, abdomen, or upper arm) 3
• Can be self-administered at home
• Latex sensitivity warning for certain formulations 2
• Expected muscle symptom rate is low (20.7%) and lower than ezetimibe 1

Follow-up monitoring:

• Check LDL-C at 12 weeks to assess response
• Target LDL-C <70 mg/dL for ASCVD patients per guidelines 4
• No routine CK monitoring needed unless symptoms develop

The evidence strongly supports immediate initiation of Repatha in confirmed statin-intolerant patients with cardiovascular disease, without requiring sequential ezetimibe failure first, given the superior efficacy and excellent muscle safety profile demonstrated in GAUSS-3 1.